19 March 2020 in Breast Cancer Research and Treatment
18 July 2018 in American Journal of Transplantation
Pirfenidone may attenuate the decline of pulmonary function in restrictive allograft syndrome (RAS) after lung transplantation. We retrospectively assessed all lung transplant recipients with RAS who were treated with pirfenidone for at least 3 months (n=11) in our lung transplant center and report on their long‐term outcomes following initiation of pirfenidone. Main outcome parameters included evolution of pulmonary function and overall survival. Pirfenidone appears to attenuate the decline in FVC and FEV1. Notably, 3 patients were bridged to redo‐transplantation with pirfenidone for 11 (5‐12) months and are currently alive, while 3 other patients demonstrate long‐term stabilization of pulmonary function after 26.6 (range 18.4‐46.6) months of treatment. Median overall 3‐year survival after RAS diagnosis was 54.5%. Subjective intolerance, mainly anorexia and nausea, necessitating pirfenidone dose de‐escalation in 55% of patients, as well as calcineurin dose increase requirements with about 20% are important complications during pirfenidone treatment after LTx. Our findings provide further evidence that pirfenidone appears to be safe and may attenuate the rate of decline in lung function in patients with RAS, but the actual clinical benefit cannot be assessed in the context of this study design and requires further investigation in a lager randomized trial.
1 February 2019 in The Journal of Heart and Lung Transplantation
1 February 2020 in The Journal of Heart and Lung Transplantation
29 May 2020 in European Respiratory Journal
Long-term survival after lung transplantation (LTx) is hampered by development of chronic lung allograft dysfunction (CLAD).Pseudomonas aeruginosais an established risk factor for CLAD. Therefore, we investigated the effect ofP. aeruginosaeradication on CLAD-free and graft survival.Patients who underwent first LTx between July, 1991, and February, 2016, and were free from CLAD, were retrospectively classified according toP. aeruginosapresence in respiratory samples between September, 2011, and September, 2016.P. aeruginosa-positive patients were subsequently stratified according to success ofP. aeruginosaeradication following targeted antibiotic treatment. CLAD-free and graft survival were compared betweenP. aeruginosa-positive andP. aeruginosa-negative patients; and between patients with or without successfulP. aeruginosaeradication. In addition, pulmonary function was assessed during the first year followingP. aeruginosaisolation in both groups.CLAD-free survival ofP. aeruginosa-negative patients (n=443) was longer compared withP. aeruginosa-positive patients (n=95) (p=0.045). Graft survival ofP. aeruginosa-negative patients (n=443, 82%) was better compared withP. aeruginosa-positive patients (n=95, 18%) (p<0.0001). Similarly,P. aeruginosa-eradicated patients demonstrated longer CLAD-free and graft survival compared with patients with persistentP. aeruginosa. Pulmonary function was higher in successfullyP. aeruginosa-eradicated patients compared with unsuccessfully eradicated patients (p=0.035).P. aeruginosaeradication after LTx improves CLAD-free and graft survival and maintains pulmonary function. Therefore, earlyP. aeruginosadetection and eradication should be pursued.
1 March 2019 in The Journal of Heart and Lung Transplantation